Io Therapeutics, Inc.

Privately held and financed start up company focused on discovery and development of small compounds that target retinoid and retinoid nuclear receptors for treatment of cancers (especially Her2+ breast cancer), neurologic diseases (especially Parkinson's disease), and autoimmune diseases (especially psoriasis). The company has two phase II clinical programs, an RXR nuclear receptor agonist in clinical trials for Parkinson's disease and an RAR alpha agonist in clinical development and trials for multiple myeloma and acute myeloid leukemia. The company has a broad set of US and International issued patents for hematologic and solid cancers, neurodegeneration of normal aging, Parkinson's, Alzheimer's, Multiple Sclerosis, ALS, and autoimmune musculoskeletal, gastrointestinal, and skin diseases.